Overview

MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED)

Status:
Terminated
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the efficacy, safety, and tolerability of an investigational treatment for patients with HIV.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Lopinavir
Protease Inhibitors
Raltegravir Potassium
Ritonavir